Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NFT Markets Stiffen The Competition For Legacy Auction Houses

When it comes to legacy auction houses, two dominate the market – Sotheby’s and Christie’s. But, as the NFT market starts challenging some of these traditional structures, it will be interesting to see how they compete. Two memorabilia companies, Funko and Topps, also just entered the NFT market. Voice of B2B, Daniel Litwin, hosted Asher…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

When it comes to legacy auction houses, two dominate the market – Sotheby’s and Christie’s. But, as the NFT market starts challenging some of these traditional structures, it will be interesting to see how they compete. Two memorabilia companies, Funko and Topps, also just entered the NFT market.

Voice of B2B, Daniel Litwin, hosted Asher Rubinstein, Partner Gallet, Dreyer & Berkey LLP, whose primary practice is around asset protection, trusts & estates, as well as representing high net-worth individuals like art collectors, designers, wine importers & producers, and other professionals in wine & hospitality, on Marketscale TV to discuss the structure NFT market and how it compares to the traditional auctions that exist today.

“I think that both of them are realizing that competition is on the horizon,” he said of Sotheby’s and Christie’s. Rubinstein noted the competition comes in the form of smaller, newer auction spaces that are dealing in the digital art spaces.

Wealthy buyers worldwide, such as Russia and the Persian Gulf, often bid on prestigious art. A lot of those bids come in anonymously. The newer auction and NFT spaces allow anonymous bids from wealthy and non-wealthy buyers. If the collectors don’t want to be known publicly, the larger auction houses will also accommodate.

Profitability is difficult in this world. Deals are often made by prominent dealers, even if that means missing out on their cut. NFTs are unlikely to change this, as they will also have to incentivize these deals.

NFTs are going to challenge the traditional auction houses. One of the main ways they will do this is to allow buyers that aren’t millionaires to make bids on priceless art.

“I think what we’re seeing here is the democratization of the art world,” Rubinstein said.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Physician burnout stems not just from workload but from loss of meaningful voice in healthcare organizations. Dr. Krishna Vedala discusses how primary care is mismanaged as a procedural business, how AI should free physicians from administrative work rather than replace them, and why physicians may need collective representation to restore trust between clinicians and administrators.

  • 01Physicians increasingly lack meaningful participation in organizational decisions, despite being closest to patients and responsible for care delivery.
  • 02Primary care requires complex, nuanced decision-making but is often managed with productivity expectations designed for procedural specialties, pushing work home and some physicians toward breaking point.
  • 03AI's highest value is reducing administrative burden and documentation so physicians have more time with patients, not replacing clinical judgment or human relationships.

Sep 8, 2026

MRI segmentation models can now label 80 structures, but deployment is the hard part

MRI segmentation models can now label 80 structures. TotalSegmentator MRI is an nnU-Net model that provides rapid segmentation of all major organs across all MRI sequences, according to Radiology Business. For health systems, deployment is the hard part.

  • 01The spread between 0.97 Dice on lungs and 0.54 on portal and splenic veins in MRSegmentator is the real operational story: enterprises need confidence flags and escalation paths, not a single headline score.
  • 02Hospitals planning radiation oncology and neuro volumetry programs can treat segmentation speedups as capacity gains only if downstream steps, contour review, dose planning inputs, and reporting templates, are standardized.

Sep 8, 2026

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512